Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: Either or both for primary renal disease?

Nephrology Dialysis Transplantation

Volumn 14, Issue 1, 1999, Pages 25-28

  McLaughlin, Kevin ^a,c   Jardine, Alan G ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c University Hospital Campus ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBERSARTAN; LOSARTAN; RENIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ARTERIAL PRESSURE; ARTICLE; COUGHING; DIABETIC NEPHROPATHY; GENOTYPE; GLOMERULOSCLEROSIS; HEART FAILURE; HUMAN; KIDNEY DISEASE; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY DISEASES; LOSARTAN; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN;

EID: 0032925128     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.1.25     Document Type: Article

References (30)

1. Homma T, Hoover RL, Ichikawa I, Harris RC. Angiotensin II (AII) induces hypertrophy and stimulates collagen production in cultured rat glomerular mesangial cells (MC) (abstract). Clin Res 1990; 38: 358A
2. El Nahas AM. Renal scarring: the role of angiotensin II. Nephrol Dial Transplant 1995; 10[Suppl 9]: 28-32
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
4. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal failure. N Engl J Med 1996; 334: 939-945
5. Hollenberg NK. ACE inhibitors, AT1 receptor blockers, and the kidney. Nephrol Dial Transplant 1997; 12: 383-383
6. Geiger H. Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect? Nephrol Dial Transplant 1997; 12: 640-642
7. Chung O, Linger T. Unopposed stimulation of the angiotensin AT2 receptor in the kidney. Nephrol Dial Transplant 1998; (in press)
8. Schulman G, Hakim R, Arias R, Silverberg M, Kaplan AP, Arbeit L. Bradykinin generation by dialysis membranes: possible role in anaphalactoid reaction. J Am Soc Nephrol 1993; 3: 1563-1569
9. Faison EP, Snavely DB, Thiyagarajan B, Nalson EB. The incidence of cough with angiotensin II receptor antagonist (Ang II RA), losartan, is significantly less than with angiotensin converting enzyme (ACE) inhibitors (ACEI) and is similar to that of placebo. Am J Hypertens 1994; 7: 34A
10. Mooser V, Nussberger J, Juillerat et al. Reactive hyperreninaemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15: 276-282
11. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilatation during angiotensin II converting enzyme inhibition. Kidney Int 1993; 44: 545-550
12. Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994; 45: 537-543
13. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771
14. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12: S37-42
15. Toto R. Losartan is an effective well-tolerated and safe antihypertensive in patients with chronic renal insufficiency (abstract). Satellite Symposium of the Int Cong Nephrol: a new class for the treatment of hypertension. Madrid 1995
16. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potent link between the renin angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001
17. Nozawa Y, Haruno A, Oda N et al. Angiotensin II receptor subtypes in bovine and human ventricular myocardium. J Pharmacol Exp Ther 1994; 270: 566-571
18. Kojima M, Shiojima I, Yamazaki T et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signalling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994; 85: 2204-2211
19. Cheung B. Increased left-ventricular mass alter losartan treatment (letter). Lancet 1997; 349: 1743-1744
20. Hebert LA, Falkenhain ME, O'Dorisio TJ. Combined ACE inhibitor (ACEI) and angiotensin II receptor antagonist (AIIra) therapy in type II diabetes with renal manifestations: effects of combined therapy on renal function (abstract). J Am Soc Nephrol 1996; 9: 1359
21. Kohzuki M, Yasujima M, Liu PF et al. Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus. Clin Exp Pharm Physiol 1995; 22: S366-367
22. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet 1997; 349: 747-752
23. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996; 156: 286-289
24. Marre M, Bernadet P, Gallois Y et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994; 43: 384-388
25. Harden P, Geddes C, Rowe P et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345: 1540-1542
26. Baboolal K, Ravine D, Daniels et al. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 1997; 52: 607-613
27. Fogarty D, Harron C, Hughes A, Nevin N, Doherty C, Maxwell P. A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes 1996; 45: 1204-1208
28. Pei Y, Scholey J, Thai K, Suzuki M, Cattran D. Association of angiotensin gene T235 variant with progression of immunoglobulin A nephropathy in caucasian patients. J Clin Invest 1997; 100: 814-820
29. Yoshida H, Mitarai T, Kawamura T et al. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96: 2162-2169
30. Tiret L, Bonnardeaux A, Poirier O et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994; 344: 910-913